Ace Therapeutics, a preclinical contract research organization specializing in analgesic drug research, has announced a comprehensive suite of end-to-end solutions for pain therapeutic development. The company offers diverse validated in vivo pain models for drug testing and a complete range of preclinical research capabilities tailored for pharmaceutical and biotechnology customers worldwide.
The services cover every stage from early target discovery and mechanism verification through pharmacological validation and safety assessment. Ace Therapeutics builds integrated in vitro and in vivo research platforms designed to study various physiological pain mechanisms, evaluate compound efficacy, and conduct safety profiling for novel analgesic candidates.
A core strength of the company lies in its extensive portfolio of standardized and customized in vivo pain models for drug testing. These span nearly all mainstream pain classifications, including migraine models established via trigeminal ganglion electrical stimulation and nitroglycerin induction, as well as neuropathic pain models such as spinal nerve ligation, chronic constriction injury, and diabetic neuropathic pain models.
To complement its in vivo systems, Ace Therapeutics has developed systematic preclinical pain assessment services encompassing mechanical, thermal, chemical, cold, and electrical stimulation pain evaluations. These use well-established testing methods like the Von Frey Filament Test, Hot Plate Test, and Formalin Test. Additionally, in vitro neuropathic pain model development services leverage dorsal root ganglion cells, iPSC-derived sensory neurons, and various co-culture systems to explore pain-related cellular mechanisms, enhancing translational value.
Beyond model construction and efficacy testing, the preclinical analgesic drug development services extend to target-based and modality-based drug discovery. These support research targeting G-protein coupled receptors, cytokine networks, and ion channels, delivering solutions for small-molecule analgesics, biologics (including antibodies, recombinant proteins, peptides), cell therapies, and gene therapy candidates. Mechanism-driven research covers peripheral inflammatory pathways, central regulatory pathways, neuronal signaling pathways, and neuro-immune interaction pathways.
The full-service pipeline includes target validation, in vitro screening, in vivo pharmacology, pharmacokinetics analysis, safety pharmacology, preclinical formulation development, and biomarker discovery. Professional PK/PD modeling, toxicity assessment, and formulation optimization help clients reduce research risks, determine optimal dosages, and accelerate candidate selection. For special needs, Ace Therapeutics can design customized pain models and testing assays according to unique drug mechanisms and research objectives.
This announcement is significant for the pharmaceutical industry as it addresses the growing demand for effective pain management therapies. The comprehensive platform may reduce development timelines and costs for novel analgesics, potentially accelerating the availability of new treatments for patients suffering from acute and chronic pain conditions. For biotech and pharma companies, access to such end-to-end services can streamline preclinical development, mitigate risks, and improve the translational success of pain drug candidates.
